Matches in Wikidata for { <http://www.wikidata.org/entity/Q92430567> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q92430567 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q92430567 description "im Dezember 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92430567 description "scientific article published on 01 December 2019" @default.
- Q92430567 description "wetenschappelijk artikel" @default.
- Q92430567 description "наукова стаття, опублікована 1 грудня 2019" @default.
- Q92430567 name "Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma" @default.
- Q92430567 name "Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma" @default.
- Q92430567 type Item @default.
- Q92430567 label "Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma" @default.
- Q92430567 label "Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma" @default.
- Q92430567 prefLabel "Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma" @default.
- Q92430567 prefLabel "Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma" @default.
- Q92430567 P1433 Q92430567-CC0D2E52-9202-41C8-A20B-9AD46873840A @default.
- Q92430567 P1476 Q92430567-C6EC6012-744B-458A-A66A-6737D4E75EA1 @default.
- Q92430567 P2093 Q92430567-1FD02BB2-26A2-48D4-9388-A266BFB11C41 @default.
- Q92430567 P2093 Q92430567-4E9FE396-C282-484E-B056-9D5C0ED526C6 @default.
- Q92430567 P2093 Q92430567-95933A67-794F-454A-B6F5-ECCC113D823C @default.
- Q92430567 P2093 Q92430567-9869379F-67AC-40F7-8EE8-BDEFC978C594 @default.
- Q92430567 P2093 Q92430567-C5DC7C0F-7BBD-478C-8829-1653FA50C845 @default.
- Q92430567 P2093 Q92430567-E70E3F2D-EC4A-47CC-8387-751E99CEA333 @default.
- Q92430567 P304 Q92430567-75B55246-58A9-42DD-A627-4C8D7292A099 @default.
- Q92430567 P31 Q92430567-DC0601BF-1224-4D78-9AD3-B9E7B480FCEA @default.
- Q92430567 P356 Q92430567-773A7FB5-FF3B-4C67-94DC-B2C549D78686 @default.
- Q92430567 P433 Q92430567-079CADC1-E94E-45F4-9CE1-9FA5684E9E32 @default.
- Q92430567 P478 Q92430567-6C17479E-2352-4835-8FA3-1D43CFDEB906 @default.
- Q92430567 P577 Q92430567-10C28FA2-3AF9-4DE1-B76A-C3BC49F36BAB @default.
- Q92430567 P698 Q92430567-3D2DA66B-016D-4605-918D-87E67728F1CA @default.
- Q92430567 P921 Q92430567-D2D43F78-0717-485D-B777-BB17C9870B67 @default.
- Q92430567 P356 EJD.2019.3671 @default.
- Q92430567 P698 31903954 @default.
- Q92430567 P1433 Q18620944 @default.
- Q92430567 P1476 "Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma" @default.
- Q92430567 P2093 "Astrid Blom" @default.
- Q92430567 P2093 "Christine Longvert" @default.
- Q92430567 P2093 "Elisa Funck-Brentano" @default.
- Q92430567 P2093 "Justine Lavaud" @default.
- Q92430567 P2093 "Magali Fort" @default.
- Q92430567 P2093 "Philippe Saiag" @default.
- Q92430567 P304 "636-640" @default.
- Q92430567 P31 Q13442814 @default.
- Q92430567 P356 "10.1684/EJD.2019.3671" @default.
- Q92430567 P433 "6" @default.
- Q92430567 P478 "29" @default.
- Q92430567 P577 "2019-12-01T00:00:00Z" @default.
- Q92430567 P698 "31903954" @default.
- Q92430567 P921 Q13896859 @default.